TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01907217

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ECT Mecta 5000M
Description: ECT is administered twice weekly with hand-held electrodes using the Mecta 5000M device following a standard stimulus dosing protocol. Seizure duration is measured by EEG monitoring. Methohexitone (0.75-1.0 mg/kg) is used for anaesthesia with suxamethonium (0.5-1.0 mg/kg) as muscle relaxant. Seizure threshold (ST) is established by a method of limits at the first session and subsequent treatments will be given at 1.5 x ST for BT ECT and 6.0 x ST for RUL ECT. To reflect routine clinical practice, number of ECT treatments is determined by referring physicians who will be blind to randomisation. The treatment period varies between patients to allow up to 12 administrations of ECT, i.e. up to 6 weeks.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ECT Mecta 5000M
Description: ECT is administered twice weekly with hand-held electrodes using the Mecta 5000M device following a standard stimulus dosing protocol. Seizure duration is measured by EEG monitoring. Methohexitone (0.75-1.0 mg/kg) is used for anaesthesia with suxamethonium (0.5-1.0 mg/kg) as muscle relaxant. Seizure threshold (ST) is established by a method of limits at the first session and subsequent treatments will be given at 1.5 x ST for BT ECT and 6.0 x ST for RUL ECT. To reflect routine clinical practice, number of ECT treatments is determined by referring physicians who will be blind to randomisation. The treatment period varies between patients to allow up to 12 administrations of ECT, i.e. up to 6 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methohexitone
Description: Methohexitone (0.75-1.0 mg/kg) is used for anaesthesia along with suxamethonium (0.5-1.0 mg/kg)for muscle relaxation. Anesthesia is the same for both arms of the trial.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methohexitone
Description: Methohexitone (0.75-1.0 mg/kg) is used for anaesthesia along with suxamethonium (0.5-1.0 mg/kg)for muscle relaxation. Anesthesia is the same for both arms of the trial.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Suxamethonium
Description: Suxamethonium (0.5-1.0 mg/kg)is used for muscle relaxation along with Methohexitone (0.75-1.0 mg/kg) for anaesthesia. Anesthesia is the same for both arms of the trial.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Suxamethonium
Description: Suxamethonium (0.5-1.0 mg/kg)is used for muscle relaxation along with Methohexitone (0.75-1.0 mg/kg) for anaesthesia. Anesthesia is the same for both arms of the trial.
Study: NCT03484221

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFOXIRI
Description: IRINOTECAN 150 mg/m\^2 IV over 1-h, day 1 + OXALIPLATIN 85 mg/m\^2 IV over 2-h, day 1 + L-LEUCOVORIN 200 mg/m\^2 IV over 2-h, day 1 + 5-FLUOROURACIL 2800 mg/m\^2 IV 48-h continuous infusion, starting on day 1 administered every two weeks for 4 cycles (2 months).

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Short-Course Radiation Therapy(5Gy*5)
Description: Patients received a short-course radiation therapy(5Gy\*5) after 4 cycles of FOLFOXIRI.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XELOX
Description: OXALIPLATIN 130 mg/m\^2 IV over 2-h, day 1 Capecitabine 1000 mg/m\^2 twice daily days 1-14 every 3 weeks for 4 cycles.
Study: NCT04407416

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Breath sampling
Description: The breath of all subjects included will be sampled using a device able to capture the alveolar air and to fix it on carbon tubes, Then the tubes will be desorbed and analysed using gas chromatography

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Breath sampling
Description: The breath of all subjects included will be sampled using a device able to capture the alveolar air and to fix it on carbon tubes, Then the tubes will be desorbed and analysed using gas chromatography

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Breath sampling
Description: The breath of all subjects included will be sampled using a device able to capture the alveolar air and to fix it on carbon tubes, Then the tubes will be desorbed and analysed using gas chromatography
Study: NCT05196906

Intervention type: PROCEDURE
Intervention: Modified Broström operation and anatomic reconstruction operation
Description: Patients with CLAI and GJL will accept the Modified Broström operation or anatomic reconstruction operation.

Intervention type: PROCEDURE
Intervention: Modified Broström operation and anatomic reconstruction operation
Description: Patients with CLAI and GJL will accept the Modified Broström operation or anatomic reconstruction operation.
Study: NCT03324828

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxyzine
Description: Hydroxyzine solution

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydroxyzine
Description: Hydroxyzine solution

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Clowns intervention
Description: Clowns intervention
Study: NCT00434577

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Herpes Zoster vaccine GSK1437173A Low Dose
Description: Single or two-dose intramuscular injection.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Herpes Zoster vaccine GSK1437173A Medium Dose
Description: Single or two-dose intramuscular injection.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Herpes Zoster vaccine GSK1437173A High Dose
Description: Single or two-dose intramuscular injection.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Herpes Zoster vaccine GSK1437173A High Dose
Description: Single or two-dose intramuscular injection.
Study: NCT03324828

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Clowns intervention
Description: Clowns intervention
Study: NCT00975858

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Coronary Revascularization
Description: revascularization of coronary arteries in case of symptomatic obstructive coronary artery disease
Study: NCT00434577

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Herpes Zoster vaccine GSK1437173A Modified
Description: Single or two-dose intramuscular injection.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single intramuscular injection
Study: NCT02821078

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 4D flow imaging sequence
Description: 4D flow imaging sequence
Study: NCT02082418

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Alpha-lactalbumin
Description: Subjects will ingest the liquid meal containing alpha-lactalbumin and carbohydrates (0.6 g/kg FFM protein + 0.3 g/kg FFM carbohydrates).

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Alpha-lactalbumin
Description: Subjects will ingest the liquid meal containing alpha-lactalbumin and carbohydrates (0.6 g/kg FFM protein + 0.3 g/kg FFM carbohydrates).

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Alpha-lactalbumin
Description: Subjects will ingest the liquid meal containing alpha-lactalbumin and carbohydrates (0.6 g/kg FFM protein + 0.3 g/kg FFM carbohydrates).

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Whey
Description: commercially available whey protein

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Whey
Description: commercially available whey protein

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Whey
Description: commercially available whey protein

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Casein
Description: commercially available casein protein

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Casein
Description: commercially available casein protein

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Casein
Description: commercially available casein protein
Study: NCT00975858

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Coronary Revascularization
Description: revascularization of coronary arteries in case of symptomatic obstructive coronary artery disease
Study: NCT02846935

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine
Description: 2-4 capsules depending on the weight of participant. Dec capsules are ingested \~60 minutes after THU capsules.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tetrahydrouridine
Description: 2-4 capsules depending on the weight of participant. Oral THU capsules followed 60 minutes later by oral Dec capsules are ingested 2X/week on consecutive days.
Study: NCT01232569

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab 162 mg
Description: Tocilizumab will be supplied in a ready-to-use, single-use, pre-filled syringe. Patients and/or caregivers will be trained to administer the injection.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be supplied in a ready-to-use, single-use, pre-filled syringe. Patients and/or caregivers will be trained to administer the injection.
Study: NCT04210375

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: JK07
Description: Recombinant fusion protein consisting of a fully humanized immunoglobulin G1 monoclonal antibody and an active polypeptide fragment of the human growth factor NRG-1

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching Placebo
Description: Vehicle control
Study: NCT01542034

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deoxycholic acid injection
Description: Formulated as an injectable solution containing deoxycholic acid at a concentration of 10 mg/mL.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Phosphate buffered saline placebo for injection
Study: NCT02804906

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Home-based physical therapy
Description: Participants will be visited by a physical therapist 3 times a week for approximately 1 hour each day, for a duration of 4 weeks. These visits will serve to encourage adherence to the intervention, reinforce activities recommended at discharge, monitor safety under direct supervision, and adjust the exercise prescription if/as needed (e.g. advance recommended activity level) if necessary. Patients will also be provided with a tablet computer device installed with software, Moving Analytics, that will reinforce the cardiac rehabilitation program through daily reminders and easily accessible visual activity plans. This program will be updated by the physical therapist during home visits as the program advances. Daily patient-reported health status (Your Activities of Daily Living) 26 will be ascertained on the same tablet device by participants three times per week using open source software designed.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Participants in the control arm will be provided with a 30-minute counseling session on risk factor modification prior to discharge. Participants will be provided with a tablet computer device to complete patient-reported health status (Your Activities of Daily Living) 26 three times per week using open source software designed. Participants will be visited by the Research Coordinator or member of the study team at one month post-hospital discharge to perform a follow-up assessment that will include ADLs, IADLs, SF-12 PCS, frailty measures, and questions on healthcare utilization (hospital readmissions).
Study: NCT03118791

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: anthocyanins
Description: Acute intake of capsules

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: anthocyanins
Description: Acute intake of capsules

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: anthocyanins
Description: Acute intake of capsules

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: anthocyanins
Description: Acute intake of capsules

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: anthocyanins
Description: Acute intake of capsules

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: anthocyanins
Description: Acute intake of capsules
Study: NCT01578954

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Reinduction/Consolidation - dose escalation of lenalidomide: Level 1 - 25mg, Level 2 - 35mg, Level 3 - 50mg, PO, QD, 28 days.~Maintenance Lenalidomide - 10mg, PO, QD, continuous dosing, 12 months
Study: NCT04291677

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: intervention musical
Description: Intervention group in which musical intervention will be applied the first or third day of mechanical ventilation.

Intervention type: OTHER
Group type: OTHER
Intervention: Without intervention musical
Description: Control group with standard treatment without musical intervention.
Study: NCT03203460

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High-intensity aerobic interval training (HIIT)
Description: A 12-week, supervised, HIIT aerobic exercise program consisting of alternating vigorous- and low-intensity intervals
Study: NCT00248976

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Net-present value of individual health behaviors in years
Study: NCT01778647

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Stimulants plus Lovaza
Description: Patients randomized to stimulants plus Lovaza (Omega-3 fatty acids). Treated and evaluated for up to 16 weeks. Conners and CGI scales filled out by parents, teachers and evaluators on each visit

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Stimulants plus placebo
Description: Patients randomized to usual dose of stimulants plus placebo. Patients evaluated for up to 16 weeks. Conners rating scales and CGI filled out by evaluators, parents and teachers.
Study: NCT01488838

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin: 40 mg/m2 weekly during radiation
Description: Cisplatin: 40 mg/m2 weekly during radiation for 7 doses

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiation: 60-66 Gy in 2 Gy daily fractions
Description: Radiation: 60-66 Gy in 2 Gy daily fractions
Study: NCT04237519

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SFL training
Description: The SFL training program comprises:~* Physical exercises: 50 video exercises to improve balance, muscle strength and physical capabilities in older adults;~* Cognitive exercises: Four ludic activities targeting problem solving (4 Images/ 1 word), memory (Quiz and Recall me), speed processing and divided attention (Attention!).~In addition, the SFL program includes a series of unique components:~* Chat rooms: to share views about topics of interest and tips for common real-life problems;~* Psycho-education content: to improve self-management and promoting cognitive transfer though 22 different topics (provide recommendations usually given in psychotherapy sessions);~* Virtual coach: to guide participants along the proposed exercises by giving them instructions, reminding them regularly to practice a variety of available activities repeatedly, providing appropriate and timely feedback on participant's performances and rewarding assiduity, perseverance and performance.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Active controlled training
Description: The active control training program is structured in the same manner as the SFL training program and will also offer different physical and cognitive activities:~* Physical exercises: 12 different exercises trains upper and lower extremity strength, mobility and balance offered through a computerized version of a health insurance company physical training program;~* Cognitive activities: Four commercially available leisure activities (Sudoku. Cross Words, Pac-Man and Countdown activities) that are appreciated by older adults but do not teach cognitive strategies and are were not designed to improve cognition per se.~No chat room, psycho-educational content or virtual coach were included in the active control training program.
Study: NCT01281215

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education interventional
Description: The patients will receive pharmaceutical education to know more about asthma, the importance of treatment compliance, the medications used to control the pathology, corrected patients' inhalation techniques and the medication care.
Study: NCT01195740

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Attachment Based Family Therapy
Description: ABFT has three phases. In phase one, treatment focuses on helping the adolescent identify past and present family conflicts that have strained the attachment bond and damaged trust. Adolescents and parents are taught new communication and affect regulation skills in preparation for reparative conversations in phase two. This phase of treatment involves adolescents and parents discussing these past and present conflicts using their new communication skills. The final phase of treatment focuses on promoting adolescent autonomy (i.e., improving school productivity, finding a job, etc.). For the suicidal/depressed adolescent, this can decrease isolation and increase exposure to positive experiences. To accomplish these goals, there are five ABFT treatment tasks. Each task may take one or several sessions. Youth randomized to this condition will receive approximately 14 weeks of ABFT. One orientation meeting will occur, whenever possible, on the inpatient unit prior to discharge.
Study: NCT03283059

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Octohydroaminoacridine Succinate
Description: Octohydroaminoacridine Succinate Tablet:4mg P.O. tid

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aricept
Description: Aricept 5mg/day, P.O.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Placebo Tablet: P.O. tid
Study: NCT03342131

Intervention type: OTHER
Intervention: Circulating wnt 2 and wnt 4 concentration
Description: Blood (150 each group) is obtained into ethylenediaminetetraacetic acid（EDTA） tubes from all subjects via antecubital venepuncture to explore circulating wnt 2 and wnt 4 concentration by ELISA. Continuous wnt2 and wnt4 concentration are measured in all patients with STEMI at 0 , 7days and 12 months after admission. Other patients with acute syndrome system are measured Wnt 2 and wnt4 only once within 24h after admission.~Wnt2 and wnt4 concentration in Control group will be measured only once with 24h after admission.

Intervention type: OTHER
Intervention: Circulating wnt 2 and wnt 4 concentration
Description: Blood (150 each group) is obtained into ethylenediaminetetraacetic acid（EDTA） tubes from all subjects via antecubital venepuncture to explore circulating wnt 2 and wnt 4 concentration by ELISA. Continuous wnt2 and wnt4 concentration are measured in all patients with STEMI at 0 , 7days and 12 months after admission. Other patients with acute syndrome system are measured Wnt 2 and wnt4 only once within 24h after admission.~Wnt2 and wnt4 concentration in Control group will be measured only once with 24h after admission.

Intervention type: OTHER
Intervention: Circulating wnt 2 and wnt 4 concentration
Description: Blood (150 each group) is obtained into ethylenediaminetetraacetic acid（EDTA） tubes from all subjects via antecubital venepuncture to explore circulating wnt 2 and wnt 4 concentration by ELISA. Continuous wnt2 and wnt4 concentration are measured in all patients with STEMI at 0 , 7days and 12 months after admission. Other patients with acute syndrome system are measured Wnt 2 and wnt4 only once within 24h after admission.~Wnt2 and wnt4 concentration in Control group will be measured only once with 24h after admission.
Study: NCT01706575

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated Interferon (Peginterferon) Alfa-2a
Description: Peginterferon alfa-2a 180 mcg, subcutaneously (SC) once weekly for 48 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nucleos(t)ide Analogues (NA)
Description: Nucleos(t)ide analogues includes adefovir, entecavir, lamivudine or tenofovir.
Study: NCT03215719

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Standard Radiation Treatment
Description: An interval scan at 4 weeks to assess for a good response defined as \>40% nodal shrinkage will stratify patients into receiving standard treatment (≤40% nodal shrinkage) or a dose-deescalated treatment regimen (\>40% nodal shrinkage). Those with nodal shrinkage and clearance of circulating plasma HPV DNA shall undergo further treatment de-escalation.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Dose-Deescalated Treatment
Description: Intensity-modulated radiation therapy (IMRT) is an advanced type of radiation therapy used to treat cancer and noncancerous tumors. IMRT uses advanced technology to manipulate photon and proton beams of radiation to conform to the shape of a tumor. Patients will be treated with intensity-modulated radiation therapy (IMRT) with megavoltage photons

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatinum
Description: Standard of care chemotherapy
Study: NCT00783224

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for MF
Description: Placebo to mometasone furoate nasal spray, indistinguishable from mometasone furoate nasal spray. Patients in this arm take 2 sprays per nostril once a day for 2 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for FP
Description: Placebo to fluticasone nasal spray, indistinguishable from fluticasone propionate nasal spray. Patients in this arm take 2 sprays per nostril twice a day for 2 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mometasone
Description: Mometasone furoate nasal spray. Patients in this arm take 2 sprays per nostril once a day for 2 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluticasone
Description: Fluticasone propionate nasal spray. Patients in this arm take 2 sprays per nostril twice a day for 2 weeks
Study: NCT00630084

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pegylated interferon alpha 2a and plus ribavirin
Description: pegylated interferon alpha 2a 180 mcg/week and Ribavirin 1000-1200 mg/day for 24 weeks, follow up for 24 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pegylated interferon alpha 2a and plus ribavirin
Description: pegylated interferon alpha 2a 180 mcg/week and Ribavirin 1000-1200 mg/day for 24 weeks, follow up for 24 weeks